First Time Loading...

Biomarin Pharmaceutical Inc
NASDAQ:BMRN

Watchlist Manager
Biomarin Pharmaceutical Inc Logo
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Watchlist
Price: 82.44 USD -1.62% Market Closed
Updated: May 5, 2024

Biomarin Pharmaceutical Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biomarin Pharmaceutical Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Revenue
$2.5B
CAGR 3-Years
10%
CAGR 5-Years
10%
CAGR 10-Years
16%
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.5B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

Biomarin Pharmaceutical Inc
Revenue Breakdown

Breakdown by Geography
Biomarin Pharmaceutical Inc

Not Available

Breakdown by Segments
Biomarin Pharmaceutical Inc

Total Revenue: 2.4B USD
100%
Net Product Revenues: 2.4B USD
98.1%
Products Excluding Aldurazyme: 2.2B USD
92.6%
Aldurazyme: 131.2m USD
5.4%
Royalty And Other Revenues: 46.7m USD
1.9%
Show More
Show Less

See Also

What is Biomarin Pharmaceutical Inc's Revenue?
Revenue
2.5B USD

Based on the financial report for Mar 31, 2024, Biomarin Pharmaceutical Inc's Revenue amounts to 2.5B USD.

What is Biomarin Pharmaceutical Inc's Revenue growth rate?
Revenue CAGR 10Y
16%

Over the last year, the Revenue growth was 14%. The average annual Revenue growth rates for Biomarin Pharmaceutical Inc have been 10% over the past three years , 10% over the past five years , and 16% over the past ten years .